Affiliations: [a] Department of Clinical Pathology and Immunology, Uppsala University Hospital, Uppsala, Sweden | [b] Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland | [c] Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland | [d] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Correspondence:
[*]
Correspondence to: Prof. Irina Alafuzoff, MD, PhD, Uppsala University/Uppsala University Hospital, Department ofImmunology, Genetics and Pathology, Rudbeck Laboratory, DagHammarskjölds väg 20, 751 85 Uppsala, Sweden. Fax: +46 18 553354; [email protected]
Abstract: For Braak staging of Alzheimer’s disease (AD), the assessment of only hippocampal section has been proposed. In two published modifications, the emphasis is on the pathology in Ammon’s horn. We investigated this approach in a cohort including 150 cases. A Braak stage was possible to assign in a subset of the cases, and the agreement rates varied from 60% to 36% . Thus, to reliably stage the AD-related neurodegeneration, regions such as the entorhinal, transentorhinal, temporo-occipital, and occipital cortices should be assessed as has also been recommended in 2012 by the National Institute on Aging - Alzheimer’s Association guidelines.
